The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

Starboard Value LP underperformed peers in 2024, a year in which Jeff Smith’s activist firm was frustrated with large ...

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...

PHILADELPHIA, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer’s Board of ...

I rate Pfizer a sell for the next 18–24 months. I expect continued headwinds from Medicare Part D redesign and patent expirations for Eliquis and Prevnar-13 in 2026. Medicare changes will cut $1 ...

Starboard woos former Pfizer CEO and CFO In October 2024, Starboard said that former Pfizer CEO Ian Read and former CFO Frank D'Amelio shared concerns about Pfizer's direction and had offered to ...

OpenAI's board chairman on Friday said it has unanimously rejected an Elon Musk-led offer to buy the hot artificial intelligence company for $97.4 billion. "OpenAI is not for sale, and the board ...

Former Nashville Predators forward Martin Erat, who faces multiple charges including driving under the influence on Feb. 1 according to Nolensville and Brentwood police records, spoke publicly ...